Tethis S.p.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tethis S.p.A. - overview
Location
Milan, -, Italy
Primary Industry
Healthcare Specialists
About
Tethis S. p. A. , based in Milan, Italy, specializes in innovative liquid biopsy solutions.
The company focuses on biological sample processing to enhance accuracy in cancer diagnostics, catering to healthcare and research sectors. Founded in Milan, Italy, Tethis S. p. A.
develops advanced diagnostics for liquid biopsies. The company has participated in 2 funding deals, with the latest round occurring on January 14, 2025, when it raised EUR 15 million from Fondazione ENEA Tech e Biomedical. The founder, Paolo Milani, has a background in healthcare innovation, while the current CEO is Daniele Scarinci, alongside Holger Neecke. Tethis specializes in providing innovative liquid biopsy solutions designed to maintain the integrity of biological samples through immediate and automated processing.
Their core product leverages a unique approach to sample handling, ensuring that samples are standardized and prepared for analysis without degradation. This technology is particularly beneficial for healthcare providers and research institutions focusing on early cancer detection and monitoring, where the accuracy and timing of sample processing are critical. Tethis serves a diverse client base, including hospitals, diagnostic labs, and research organizations, primarily in the North American and European markets, where the demand for reliable and efficient diagnostic tools is growing. In the most recent fiscal year 2023, Tethis reported revenue of EUR 114,842.
10, with an EBITDA of EUR -2,321,579. 80. The company generates revenue through strategic partnerships and B2B transactions, focusing on healthcare institutions and laboratories. In January 2025, Tethis S.
p. A. raised EUR 15 million in venture funding, co-led by Fondazione ENEA Tech e Biomedical and Biomedical Foundation. This funding will be utilized to advance, test, and prepare their diagnostic platform for market launch, aiming for expansion into new geographic regions and heightened service capabilities in North America and Europe.
Current Investors
Fondazione ENEA Tech e Biomedical, Genextra S.p.A., Agite! S.p.A.
Primary Industry
Healthcare Specialists
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.tethis-lab.com
Verticals
Nanotechnology
Company Stage
Growth Stage/Expansion
Total Amount Raised
Subscriber access only
Tethis S.p.A. - timeline of key events
Tethis S.p.A. - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 208,038 | 249,481 | 257,384 | 331,025 | 73,568 | 323,478 | 591,445 | 320,869 | 283,270 | 174,338 | 170,454 | 224,640 | - | - | - |
| % Revenue Growth (YoY) | - | 19.9% | 3.2% | 28.6% | (77.8%) | 339.7% | 82.8% | (45.7%) | (11.7%) | (38.5%) | (2.2%) | 31.8% | - | - | - |
| EBITDA (USD) | (1,304,365) | (1,189,828) | (1,252,545) | (1,261,986) | (1,488,658) | (1,753,033) | (374,373) | (1,297,198) | (1,691,449) | (2,134,371) | (1,575,174) | (1,798,908) | - | - | - |
| Operating Income (USD) | (1,617,454) | (1,497,130) | (1,496,239) | (1,474,074) | (1,673,128) | (1,916,204) | (507,161) | (1,432,480) | (1,833,075) | (2,278,782) | (1,774,776) | (2,024,904) | - | - | - |
| Operating Margin | (777.5%) | (600.1%) | (581.3%) | (445.3%) | (2274.3%) | (592.4%) | (85.7%) | (446.4%) | (647.1%) | (1307.1%) | (1041.2%) | (901.4%) | - | - | - |
| % EBITDA Margin | (627.0%) | (476.9%) | (486.6%) | (381.2%) | (2023.5%) | (541.9%) | (63.3%) | (404.3%) | (597.1%) | (1224.3%) | (924.1%) | (800.8%) | - | - | - |
| NET Income (USD) | (1,556,548) | (1,493,468) | (1,497,515) | (1,474,807) | (1,671,381) | (2,545,417) | (1,184,710) | (1,957,289) | (2,401,192) | (2,572,200) | (1,778,019) | (2,025,025) | - | - | - |
| % Net Margin | (748.2%) | (598.6%) | (581.8%) | (445.5%) | (2271.9%) | (786.9%) | (200.3%) | (610.0%) | (847.7%) | (1475.4%) | (1043.1%) | (901.5%) | - | - | - |
Tethis S.p.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.